Skip to main content
Log in

First-line pertuzumab combination therapy not cost effective for BC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. human epidermal growth factor receptor-2

  2. 2020 US dollars

Reference

  • Moriwaki K, et al. Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan. PharmacoEconomics-Open : 23 Jan 2021. Available from: URL: https://doi.org/10.1007/s41669-020-00254-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

First-line pertuzumab combination therapy not cost effective for BC. PharmacoEcon Outcomes News 871, 17 (2021). https://doi.org/10.1007/s40274-021-7455-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7455-z

Navigation